J. Li

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS

Kei Muro, Eric Van Cutsem, Yukiya Narita et al. · Annals of Oncology · 2018 · 214 citations · Full text

514O An open-label, global, first-in-human study of SKB264 in patients with locally advanced or metastatic solid tumors

Jordi Rodón, J. Li, Junli Xue et al. · Annals of Oncology · 2021 · 14 citations

Medicine, Pathology, Cancer Genomics +7

Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): first results of the CheckMate 8HW study

G. Folprecht, Thierry André, Élena Elez et al. · Zeitschrift für Gastroenterologie · 2024 · 14 citations

Medicine, Immunology, Metastatic Colorectal Cancer +7

P-12 A phase 3 study of nivolumab (NIVO), NIVO + ipilimumab (IPI), or chemotherapy for microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): CheckMate 8HW

Thierry André, E. Van Cutsem, Elena Élez et al. · Annals of Oncology · 2022 · 13 citations

Medicine, Immunology, Colorectal Cancer +6

1445P CS1001, an anti-PD-L1 antibody, combined with standard of care (SOC) chemotherapy for first line (1L) advanced GC/GEJ and ESCC: Preliminary results from 2 phase Ib cohorts of CS1001-101 study

Lin Shen, J. Li, Z H Miao et al. · Annals of Oncology · 2020 · 11 citations

Anti-pd-l1 Antibody, Cs1001-101 Study, First Line +10